{"id":118081,"date":"2026-02-19T14:32:10","date_gmt":"2026-02-19T14:32:10","guid":{"rendered":"https:\/\/www.newsbeep.com\/us-pa\/118081\/"},"modified":"2026-02-19T14:32:10","modified_gmt":"2026-02-19T14:32:10","slug":"jj-plans-1b-investment-in-pa-cell-therapy-manufacturing-facility","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/us-pa\/118081\/","title":{"rendered":"J&#038;J Plans $1B Investment in PA Cell Therapy Manufacturing Facility"},"content":{"rendered":"<p>Johnson &amp; Johnson has <a class=\"Link\" href=\"https:\/\/www.biospace.com\/press-releases\/johnson-johnson-expands-u-s-footprint-with-more-than-1-billion-investment-in-next-generation-cell-therapy-manufacturing-facility-in-pennsylvania\" target=\"_blank\" rel=\"noopener nofollow\">committed<\/a> more than $1 billion to build a cell therapy manufacturing facility in Pennsylvania.<\/p>\n<p>The plant, which is part of J&amp;J\u2019s push <a class=\"Link\" href=\"https:\/\/www.biospace.com\/business\/j-j-joins-pharma-peers-with-55b-us-manufacturing-boost-following-trumps-tariff-threats\" target=\"_blank\" rel=\"noopener nofollow\">to invest<\/a> $55 billion in the U.S. by early 2029, was first <a class=\"Link\" href=\"https:\/\/www.biospace.com\/press-releases\/johnson-johnson-reaches-agreement-with-u-s-government-to-improve-access-to-medicines-and-lower-costs-for-millions-of-americans-delivers-on-u-s-manufacturing-and-innovation-investments\" target=\"_blank\" rel=\"noopener nofollow\">disclosed<\/a> last month, but few details were available at that time. J&amp;J shared more information Wednesday, revealing it will build the plant in Montgomery County. The facility will employ 500 people when fully operational. Pennsylvania state authorities <a class=\"Link\" href=\"https:\/\/www.pa.gov\/governor\/newsroom\/2026-press-releases\/gov-shapiro-secures--1-billion-investment-from-j-j-to-build-new-\" target=\"_blank\" rel=\"noopener nofollow\">said<\/a> J&amp;J will create the jobs over the next 12 years.<\/p>\n<p>At a press conference, J&amp;J CEO Joaquin Duato <a class=\"Link\" href=\"https:\/\/filesource.amperwave.net\/commonwealthofpa\/mp4_podcast\/28973_gov_jjAnnouncement_clean.m4v\" target=\"_blank\" rel=\"noopener nofollow\">said<\/a> construction will start in the second half of 2026. J&amp;J expects to begin making cell therapies for patients at the facility in 2031. Duato said the company will hire some of the planned 500 employees \u201cmuch earlier\u201d so they can perform validation work at the plant.<\/p>\n<p>The facility will support an emerging cell therapy portfolio. J&amp;J <a class=\"Link\" href=\"https:\/\/www.biospace.com\/johnson-and-johnson-legend-biotech-win-fda-approval-for-car-t-therapy\" target=\"_blank\" rel=\"noopener nofollow\">won<\/a> FDA approval for the BCMA-directed CAR T cell therapy Carvykti in 2022. The company and its partner Legend Biotech <a class=\"Link\" href=\"https:\/\/investors.legendbiotech.com\/node\/8556\/html\" target=\"_blank\" rel=\"noopener nofollow\">struck<\/a> a five-year deal to outsource production of the cell therapy to Novartis in 2024. Sales of Carvykti almost <a class=\"Link\" href=\"https:\/\/www.investor.jnj.com\/investor-news\/news-details\/2026\/Johnson--Johnson-reports-Q4-and-Full-Year-2025-results\/default.aspx\" target=\"_blank\" rel=\"noopener nofollow\">doubled<\/a> in 2025 to hit $1.9 billion.<\/p>\n<p>J&amp;J\u2019s pipeline includes a CD20-based CAR T that the company <a class=\"Link\" href=\"https:\/\/www.investor.jnj.com\/pipeline\/novel-therapies\/default.aspx\" target=\"_blank\" rel=\"noopener nofollow\">predicts<\/a> could have annual sales in excess of $5 billion, suggesting it may need additional cell therapy manufacturing capacity in the future. Duato said that when fully operational, the new site will \u201cserve thousands of patients each year, shortening delivery times for these very personalized therapies.\u201d<\/p>\n<p>Discussing the selection of Pennsylvania over other locations, Duato said the state has a deep talent pool and great academic institutions and community colleges. Pennsylvania is awarding up to $2.5 million to a local community college or technical school to help create a workforce development training program for J&amp;J. The money is part of a $41.5 million package of tax credits, grants and other financial support.<\/p>\n<p>Philadelphia, which is close to J&amp;J\u2019s planned site in Montgomery County, is a hub for cell therapies. Led by researchers including Carl June and Bruce Levine, teams at Penn Medicine and Children\u2019s Hospital of Philadelphia pioneered CAR T cell therapies by driving early development of Novartis\u2019 Kymriah.<\/p>\n<p>Cell and gene therapy startups have spun out of Philadelphia institutions, and the concentration of talent has attracted other companies. Iovance makes tumor-infiltrating lymphocyte cell therapies at a plant in Philadelphia, and cell therapy contract manufacturer Minaris Advanced Therapies is based in the city.<\/p>\n<p>    <a class=\"Link\" aria-label=\"Eli Lilly Commits $3.5B To Build Injectable Obesity Drug Plant in PA\" href=\"https:\/\/www.biospace.com\/business\/eli-lilly-commits-3-5b-to-build-injectable-obesity-drug-plant-in-pa\" rel=\"nofollow noopener\" target=\"_blank\"><\/p>\n<p>    <img decoding=\"async\" class=\"Image\" alt=\"Welcome to Pennsylvania sign at the Pennsylvania\/New York state line along Interstate 90.\"  width=\"100\" height=\"100\" src=\"https:\/\/www.newsbeep.com\/us-pa\/wp-content\/uploads\/2026\/02\/1771511530_459_.jpeg\" loading=\"lazy\"\/><\/p>\n<p><\/a><\/p>\n<p>\n        The facility, which is part of Lilly\u2019s $50 billion reshoring drive, will make obesity drugs such as tirzepatide and retatrutide when it starts operations in 2031.\n    <\/p>\n<p>February 2, 2026<\/p>\n<p>\u00a0\u00b7\u00a0<\/p>\n<p>2 min read<\/p>\n<p>\u00a0\u00b7\u00a0<\/p>\n<p>The J&amp;J plant is the second win in quick succession for Pennsylvania. Three weeks ago, Eli Lilly <a class=\"Link\" href=\"https:\/\/www.biospace.com\/business\/eli-lilly-commits-3-5b-to-build-injectable-obesity-drug-plant-in-pa\" target=\"_blank\" rel=\"noopener nofollow\">set out<\/a> plans to spend $3.5 billion to build a manufacturing facility for injectable weight-loss therapies in Lehigh Valley.<\/p>\n","protected":false},"excerpt":{"rendered":"Johnson &amp; Johnson has committed more than $1 billion to build a cell therapy manufacturing facility in Pennsylvania.&hellip;\n","protected":false},"author":2,"featured_media":118082,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[28,30,29],"class_list":{"0":"post-118081","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-pennsylvania","8":"tag-pennsylvania","9":"tag-pennsylvania-headlines","10":"tag-pennsylvania-news"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/posts\/118081","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/comments?post=118081"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/posts\/118081\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/media\/118082"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/media?parent=118081"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/categories?post=118081"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us-pa\/wp-json\/wp\/v2\/tags?post=118081"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}